Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL5170955 | 1.00 | MEN1 (0.31) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL8002259 | 0.96 | — | — | |
| Sulfuric Acid SCHEMBL11244617 | 0.96 | MEN1 (0.38) | MEN1ALDH1A1TSHRKMT2A | |
| Sulfuric Acid SCHEMBL8407760 | 0.96 | — | — | |
| SCHEMBL31728826 | 0.96 | MEN1 (0.33) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Potassium Ion SCHEMBL8748 | 0.96 | MEN1 (0.33) | MEN1ALDH1A1TSHRKMT2A | |
| Potassium Ion SCHEMBL29775431 | 0.96 | MEN1 (0.33) | MEN1ALDH1A1TSHRKMT2A | |
| Sulfuric Acid SCHEMBL28227978 | 0.93 | — | — | |
| Sulfuric Acid SCHEMBL8407341 | 0.92 | TSHR (0.40) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL2808564 | 0.92 | MEN1 (0.31) | MEN1ALDH1A1TSHRKMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207146-B2 | Phenothiazine derivative having a double bond, method for the production thereof, and use thereof as a pharmaceutical | SANOFI-AVENTIS (FR) | 2012-06-26 | — | — | US | disclosed |
| EP-2203448-B1 | PHENOTHIAZINE DERIVATIVE HAVING A DOUBLE BOND, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A PHARMACEUTICAL | SANOFI AVENTIS (FR) | 2011-06-22 | — | — | EP | disclosed |
| US-20100261643-A1 | PHENOTHIAZINE DERIVATIVE HAVING A DOUBLE BOND, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A PHARMACEUTICAL | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | disclosed |
| US-5380719-A | Quinoxaline biphenyl angiotensin II inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1995-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261643-A1 | PHENOTHIAZINE DERIVATIVE HAVING A DOUBLE BOND, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A PHARMACEUTICAL | QDPR, DYRK4, CLK4 | MEN1 2839/4885ALDH1A1 804/4885TSHR 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.